Transventricular Mitral Valve Repair in Patients with Acute Forms of Ischemic Mitral Regurgitation

Transventricular mitral valve surgery combined with left ventricular restoration avoids atriotomy and provides a larger operative field. We describe a series of 5 patients in whom we performed transventricular mitral valve repair by various techniques, such as band annuloplasty, papillary muscle reattachment, chordal cutting, and edge-to-edge repair.The more acute forms of ischemic mitral regurgitation, as found in our patients, can coexist with post-myocardial infarction contained rupture or post-myocardial infarction ventricular septal rupture. Because these patients already have an indication for ventriculotomy, concomitant transventricular repair of the mitral valve can render a separate atriotomy unnecessary and thereby shorten the duration of cardiopulmonary bypass. Moreover, in patients with acute presentations, the absence of atrial dilation (this last associated with chronic cases) might make transventricular repair a better choice than the more difficult atrial approach.     

Systolic Papillary Muscle Dyssynchrony Predicts Recurrence of Mitral Regurgitation in Patients with Ischemic Cardiomyopathy (ICM) Undergoing Mitral Valve Repair

Objective: We investigated the impact of papillary muscle dyssynchrony (DYS‐PAP) in predicting recurrent mitral regurgitation (MR) in patients with ischemic cardiomyopathy (ICM) undergoing undersized mitral ring annuloplasty (UMRA). Methods: One hundred forty‐four ICM patients (left ventricular ejection fraction <35%) in sinus rhythm undergoing UMRA between January 2001 and December 2010 at three Institutions (University Hospital, Maastricht, The Netherlands; Careggi Hospital, Florence, Italy; Civic Hospital, Brescia, Italy) were recruited. The primary endpoint was the recurrence of MR at the latest echocardiographic study defined as insufficiency ≥2+ in patients with no/trivial MR at discharge. The assessment of DYS‐PAP was performed by applying two‐dimensional (2D) speckle‐tracking imaging. Results: In patients with MR recurrence, DYS‐PAP significantly worsened (84.1 ± 8.8 msec vs.65.4 ± 8.8 msec at baseline, P < 0.001) whereas in patients with no MR recurrence, DYS‐PAP did not vary (22.3 ± 5.3 msec vs. 25.9 ± 7.2 msec at baseline, P = 0.8). Recurrent MR was positively correlated with preoperative DYS‐PAP (P < 0.001), baseline anterior mitral leaflet tethering angle α (P < 0.001) and tethering symmetry index α/β before surgery (P < 0.001). There was no significant correlation between MR recurrence and other echocardiographic parameters. Logistic regression analysis revealed that baseline values of DYS‐PAP (OR: 5.4 [95% CI: 3.1–7.7], P < 0.001), α (OR: 5.0 [2.6–6.7], P < 0.001), and α/β (OR: 3.9 [2.5–5.7], p < 0.001) were predictors of recurrent MR. A DYS‐PAP value ≥ 58 msec predicted recurrence of MR with 100% sensitivity and 83% specificity (area under the curve [AUC]: 0.92 [0.7–1], P < 0.001). Conclusions: A DYS‐PAP cutoff value of 58 msec is useful to identify patients in whom UMRA is likely to fail. That way decision making in ischemic functional MR might be facilitated.     

缺血性二尖瓣关闭不全的外科治疗

目的：本文旨在回顾性研究单中心外科治疗缺血性二尖瓣关闭不全的临床经验。方法：回顾性分析279例缺血性二尖瓣关闭不全患者的临床资料。平均年龄59.2±7.4岁。心功能分级II级141例,III级117例,IV级21例。左室舒末内径57~91mm ,左室射血分数20%~59%。二尖瓣反流程度：中度156例,中-重度75例,重度48例。冠脉造影结果三支病变240例,两支病变30例,单支病变9例。结果：二尖瓣成形术224例,术后即刻TEE示无返流152例,微量返流43例,微量-轻度21例,轻度8例。二尖瓣置换术75例,IABP辅助37例。冠状动脉旁路移植远端吻合口3.6±0.5个。手术死亡13例,死亡率4.7%（13/279）。出院时左室舒末内径46~86mm,左室射血分数20%~62% 。二尖瓣无反流232例,微量26例,轻度12例,轻-中度7例,中度2例。 结论：外科治疗冠心病合并缺血性二尖瓣关闭不全可获得满意的治疗效果,尤其是对于射血分数降低、左心增大、心力衰竭的患者,获益更大。     

Outcomes After Transcatheter Edge-to-Edge Mitral Valve Repair According to Mitral Regurgitation Etiology and Cardiac Remodeling

BackgroundTranscatheter edge-to-edge repair (TEER) has been increasingly used for selected patients with mitral regurgitation (MR), but limited data are available regarding clinical outcomes in patients with varied etiology and mechanism of MR.ObjectivesThe aim of this study was to evaluate the outcomes of TEER according to etiology and left ventricular (LV) and left atrial remodeling.MethodsConsecutive patients who underwent TEER between 2007 and 2020 were included in the analysis. Among patients with functional MR (FMR), those with predominant LV remodeling were classified as having ventricular FMR (v-FMR), whereas those without LV remodeling but predominant left atrial remodeling were classified as having atrial FMR (a-FMR). The primary outcome was a composite of all-cause mortality and heart failure hospitalization at 2 years and was compared among patients with degenerative MR (DMR), a-FMR, and v-FMR.ResultsA total of 1,044 patients (11% with a-FMR, 48% with v-FMR, and 41% with DMR) with a mean Society of Thoracic Surgeons score of 8.6 ± 7.8 underwent TEER. Patients with a-FMR had higher rates of atrial fibrillation and severe tricuspid regurgitation with larger left and right atria, whereas patients with v-FMR had lower LV ejection fractions with larger LV dimensions. Residual MR more than moderate at discharge was not significantly different among the 3 groups (5.2% vs 3.2% vs 2.6%; P = 0.37). Compared with patients with DMR, 2-year event rates of the primary outcome were significantly higher in patients with a-FMR and v-FMR (21.6% vs 31.5% vs 42.3%; log-rank P < 0.001).ConclusionsDespite excellent procedural outcomes, patients with a-FMR and v-FMR had worse clinical outcomes compared with those with DMR.     

Mitral Valve Repair for Isolated Mitral Valve Regurgitation: A Plea for Early Operation

Although mitral valve repair is a recognized method to surgically treat mitral valve regurgitation, the ideal timing of the operation still is controversial. The goal of this study was to study the long-term results of mitral valve repair focusing on symptomatic versus nonsymptomatic patients. From October 1988 to June 1994, 262 patients (mean age = 57.4) with isolated mitral regurgitation underwent mitral valve repair. Seventy-nine patients (group I) were nonsymptomatic (NYHA Class I or II) and 184 (group II) were severely symptomatic (NYHA III or IV). The surgical techniques have been mainly those described by Alain Carpentier. All patients but three had an annuloplasty with a Carpentier ring. Mean follow-up was 4.02 ± 0.1 years and total follow-up, 972 patient-years. There was one operative death (0.4%). Postoperative Doppler echocardiography showed satisfactory mitral valve function in 97% of the patients and two cases of systolic anterior motion (1%). At 7 years, actuarial survival was 80%± 9%, 95%± 5%, 75%± 11% for the total group, group I, and group II, respectively. At 7 years, freedom from thromboembolic or bleeding complications and reoperation was 96%± 4%, 93%± 8%, and 94%± 3%, respectively. Mitral valve repair for isolated mitral valve regurgitation provides satisfactory survival at 7 years. The long-term survival is better when patients are operated at an early stage when they are still nonsymptomatic.     

Percutaneous Mitral Valve Repair in Cardiac Amyloidosis and Severe Mitral Regurgitation

Amyloidosis is an infiltrative disease with severe impact on the cardiac anatomy resulting in structural changes¹. Mitral valve insult from the infiltrative process, although rare, has been known to cause severe mitral regurgitation⁴. Due to underlying comorbidities these patients may not be surgical candidates.^17,18,19,20 The role of percutaneous mitral valve repair in cardiac amyloidosis has been described in a few prior cases.^4,15 We review the epidemiology, diagnosis, and treatment of cardiac amyloidosis. We also highlight prior cases described in the literature of cardiac amyloidosis and severe mitral regurgitation, while discussing the role of percutaneous mitral valve repair in these patients.     

Percutaneous vs Surgical Repair of Mitral Valve Regurgitation: Single Institution Early and Midterm Outcomes

Background

The objective of this study was to compare outcomes of surgical repair (SR) vs MitraClip (MC) implantation for severe mitral regurgitation (MR).

Methods

A retrospective analysis of patients treated within a single institution was performed. Patients had EuroSCORE [European System for Cardiac Operative Risk Evaluation] < 20%, left ventricular ejection fraction ≥45%, and grade 3+/4+ MR.

Results

Fifty patients (24 [48%] MC group, 26 [52%] SR group) with EuroSCORE 7.9 ± 5.6 were included. The MC group included 24 (48%) and the SR group 26 (52%) patients. Patients in the MC group had a significantly more complex comorbid profile (P < 0.001). Successful MC placement was in 22 patients (91.7%) and SR in 26 (100%). At discharge, no patient had grade 3+/4+ MR. There were no in hospital or 30-day deaths. At follow-up (mean 526 ± 398 days), further mitral valve surgery was necessary in 1 (3.8%) patient in the SR group and in 2 (8.3%) patients in the MC group (P = 0.26). One-year freedom from composite end point (death, stroke, myocardial infarction, major bleeding, cardiac rehospitalization) was 75.5% (SR 83% vs MC 67%; P = 0.18). Degree of residual MR Degree of residual MR immediately after the procedure was equally distributed in both groups (P = 0.13) and the sole independent determinant for composite outcome (odds ratio, 16.9; P = 0.024).

Conclusions

MC in nonsurgical candidates and SR in surgical patients showed similar perioperative and follow-up outcomes at an institution experienced with both techniques. Neither MC nor SR were independently related to outcome whenever similar degrees of acute correction with minimal residual MR were achieved. However, these findings should be interpreted within the selection biases and the numerical limitations of the present study.     

二尖瓣关闭不全的介入治疗新进展

为了减轻二尖瓣关闭不全外科手术和体外循环所带来的创伤和风险,基于外科边对边缝合和瓣环成形的手术方式,近年来二尖瓣关闭不全的介入治疗得到了快速发展,包括经二尖瓣边对边修补术和瓣环成形术,前者经穿房间隔途径送入钳夹装置或负压抽吸缝合装置,钳夹或缝合前后瓣边缘,形成双孔二尖瓣,后者经右颈内静脉途径把缩环装置植入冠状静脉窦内,缩短瓣环前后径,以减轻二尖瓣反流。两种方法均已从动物实验过渡到临床试验,均显示了良好的治疗作用,但还需技术上的进一步改进和长期大规模的临床评价。     

Percutaneous Mitral Valve Repair Vs. Stand-Alone Medical Therapy in Patients with Functional Mitral Regurgitation and Heart Failure

BackgroundFunctional mitral regurgitation (FMR) is a common finding among patients with heart failure (HF) and it is related to adverse events. Outcomes in patients undergoing transcatheter mitral valve repair (TMVR) are still a matter of debate. We performed a meta-analysis to assess mid- and long-term outcomes of patients with FMR treated with MitraClip® compared to medical management.MethodsWe conducted an electronic database search of all published data PubMed Central, Embase, the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and Google Scholar databases. The primary end-point was all-cause mortality. The secondary end-points were hospitalizations for HF, need for heart transplantation or left ventricular assist device, unplanned mitral valve surgery, myocardial infarction and stroke.ResultsFive studies (n = 1513 patients) were included in the analysis. The summary estimate including all the available studies showed a statistically significant reduction in all-cause mortality favoring MitraClip® (HR 0.56, CI 95% [0.38–0.84]) and HF hospitalizations (HR 0.65; CI 95% [0.46–0.92]). A significant reduction in the indication for advanced HF therapies (OR 0.48; CI 95% [0.25–0.90]) or the need for unplanned mitral valve surgery (OR 0.20; CI 95% [0.07–0.57]) was also found in the group of patients that underwent TMVR. No differences in the incidence of myocardial infarction or stroke were found between both groups of treatment. No publication bias was detected.ConclusionTMVR with MitraClip® system was related to a significant reduction in all-cause mortality, hospitalizations for HF and the need for HF transplant, left ventricular assist device or unplanned surgery beyond 1-year follow up.